Aquestive Therapeutics, Inc. - Common Stock (AQST)
Frequently Asked Questions About Aquestive Therapeutics, Inc. - Common Stock (AQST)
How can investors get more information about Aquestive Therapeutics?
Investors can obtain more information about Aquestive Therapeutics by visiting the company's official website, where they can access financial reports, investor presentations, press releases, and details about upcoming investor events. Additionally, interested parties can follow financial news sources and consult with financial advisors for market insights related to AQST.
How does Aquestive contribute to patient care?
Aquestive Therapeutics contributes to patient care by focusing on innovative drug delivery solutions that simplify the administration of complex medications. By developing user-friendly formulations and systems, the company aims to improve patient adherence to therapy and ultimately enhance health outcomes for individuals with chronic conditions.
How does Aquestive engage with the community?
Aquestive Therapeutics actively engages with the community through various initiatives, including outreach to patients, healthcare professionals, and advocacy groups. The company seeks to educate stakeholders about its products, support patient education efforts, and contribute positively to the overall healthcare ecosystem.
How does Aquestive ensure compliance with regulatory standards?
Aquestive Therapeutics maintains rigorous compliance with regulatory standards set forth by organizations such as the FDA and other global health authorities. The company follows Good Manufacturing Practices (GMP) and conducts thorough preclinical and clinical studies to ensure the safety, efficacy, and quality of its products before seeking approval for commercialization.
How has Aquestive performed financially?
As a publicly traded company, Aquestive Therapeutics provides regular updates on its financial performance through quarterly and annual reports. The company typically reports on revenue generated from product sales, investment in research and development, and other financial indicators, reflecting its growth opportunities and challenges in the biopharmaceutical landscape.
Is Aquestive Therapeutics publicly traded?
Yes, Aquestive Therapeutics, Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol 'AQST'. The company went public in 2018, allowing it to raise capital for its drug development initiatives and expand its operations to further its therapeutic pursuits.
What are some challenges faced by Aquestive?
Like many companies in the biopharmaceutical industry, Aquestive faces challenges including regulatory hurdles, competition in the market, and the complexities of clinical trials. Additionally, successfully translating innovative technologies into viable commercial products requires ongoing investment and strategic planning to mitigate risks.
What are some future goals for Aquestive?
Looking ahead, Aquestive Therapeutics aims to expand its product portfolio by advancing existing candidates in its pipeline and exploring new therapeutic areas. The company is focused on enhancing its drug delivery technologies and establishing further commercial partnerships to maximize the potential of its innovations and drive sustainable growth.
What are the types of technologies that Aquestive utilizes?
Aquestive utilizes a range of proprietary drug delivery technologies, including its SUBLINGUAL film platform, which allows for fast and efficient absorption of medications via the sublingual route. Additionally, the company has developed oral dissolution systems that can enhance the bioavailability and patient experience of orally administered drugs.
What does Aquestive Therapeutics, Inc. do?
Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics that are designed to address unmet medical needs in various therapeutic areas. The company specializes in utilizing its proprietary drug delivery technologies to create oral formulations of complex drugs, targeting conditions such as epilepsy and other central nervous system disorders.
What is the market status of Aquestive's lead product?
Aquestive's lead product is KYNMOBI® (apomorphine) sublingual film, which has been approved by the FDA for the treatment of 'off' episodes in Parkinson's disease patients. The product represents a novel approach for delivering apomorphine, allowing for rapid absorption and onset of action, enhancing the quality of life for patients with Parkinson's.
What is the mission of Aquestive Therapeutics?
The mission of Aquestive Therapeutics is to improve the lives of patients by developing innovative drug delivery solutions that address unmet medical needs. The company strives to transform complex medications into easier-to-administer forms, thereby enhancing patient adherence and overall treatment outcomes.
What is the primary focus of Aquestive's research and development?
The primary focus of Aquestive's research and development is on advancing drug delivery technologies, particularly for complex medications that require alternative delivery methods. The company aims to develop therapeutic solutions that enhance patient adherence, efficacy, and convenience, particularly for individuals with conditions such as epilepsy.
What is the significance of the company's ticker symbol AQST?
The ticker symbol 'AQST' represents Aquestive Therapeutics on the Nasdaq stock exchange. This unique identifier is used by investors and financial analysts to track the company’s stock performance and trading activity, reflecting the market's assessment of the company's growth potential and overall value.
What is the status of Aquestive's product pipeline?
Aquestive Therapeutics has a robust pipeline of product candidates, including therapies at various stages of development from preclinical to clinical trials. The company actively seeks to advance these candidates to market, with a particular emphasis on treatments for neurological disorders and other diseases that currently lack adequate therapeutic options.
What partnerships has Aquestive formed?
Aquestive Therapeutics has formed strategic partnerships with various organizations, including other biopharmaceutical companies, academic institutions, and healthcare organizations. These collaborations aim to leverage complementary expertise, technologies, and resources to advance the research and development of innovative therapeutics.
What sets Aquestive apart from its competitors?
Aquestive Therapeutics distinguishes itself from competitors through its proprietary drug delivery technologies and commitment to addressing complex therapeutic needs. The company focuses on developing formulations that improve patients' experiences while also aiming to fill significant gaps in treatment options within the biopharmaceutical landscape.
When was Aquestive Therapeutics, Inc. founded?
Aquestive Therapeutics, Inc. was founded in 2006, emerging from the need to improve the delivery of medications. Since its inception, the company has worked to innovate and develop treatments that translate advanced drug delivery technologies into clinical solutions for patients.
Where is the headquarters of Aquestive Therapeutics located?
The headquarters of Aquestive Therapeutics, Inc. is located in Warren, New Jersey. This strategic location allows the company to collaborate with leading academic institutions, research facilities, and healthcare providers to further its mission of improving patient outcomes through innovative therapies.
Who are the key members of Aquestive's leadership team?
The leadership team at Aquestive Therapeutics includes experienced professionals from the pharmaceutical and biotechnology industries, with expertise in drug development, regulatory affairs, and commercialization. Key figures typically include the CEO, COO, and other executives who guide the company's strategic direction and operational execution.
What is the current price of Aquestive Therapeutics, Inc. - Common Stock?
The current price of Aquestive Therapeutics, Inc. - Common Stock is 3.700
When was Aquestive Therapeutics, Inc. - Common Stock last traded?
The last trade of Aquestive Therapeutics, Inc. - Common Stock was at 4:00 pm EDT on July 7th, 2025
What is the market capitalization of Aquestive Therapeutics, Inc. - Common Stock?
The market capitalization of Aquestive Therapeutics, Inc. - Common Stock is 143.88M
How many shares of Aquestive Therapeutics, Inc. - Common Stock are outstanding?
Aquestive Therapeutics, Inc. - Common Stock has 38.89M shares outstanding.